TP53 and prostate adenocarcinoma: In support of this hypothesis, in one (P2) of the two prostate samples that we extensively profiled by scCUTseq, we found that tumor regions were enriched in multiple phylogenetically related subclones with a monoallelic loss of multiple TSGs, including BRCA2, CCNC, CDX2, FOXO1, FOXO3, LATS2, PRDM1, and RB1. These TSGs are frequently deleted alone or in various combinations in prostate adenocarcinomas (PRADs) in TCGA and RB1 has been shown to be frequently deleted with TP53 and PTEN in localized prostate cancers29.